Pine River Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Pine River Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,600	Closed	-$425K	–	796
2015 Q1	$425K	Buy	+3,600	New	+$431K	0.01%	530
2014 Q4	–	Sell	-8,800	Closed	-$988K	–	960
2014 Q3	$988K	Buy	8,800 +5,400	+159%	+$514K	0.01%	632
2014 Q2	$322K	Buy	+3,400	New	+$238K	0.01%	643

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pine River Capital Management's VRTX Position: Q2 2015 in Review

Pine River Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2015, closing a stake of 3,600 shares — an estimated $425K sold.

Pine River Capital Management first reported a position in VRTX in Q2 2014 and held it in 3 quarters. The position peaked at $988K in Q3 2014. 500 funds tracked by Wall St. Rank hold VRTX as of Q2 2015.

Pine River Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Pine River Capital Management sold 3,600 Vertex Pharmaceuticals shares in Q2 2015, an estimated $425K.
Pine River Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Pine River Capital Management's Vertex Pharmaceuticals position peaked at $988K in Q3 2014.
500 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2015.

Based on Pine River Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.